Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: Results of the German Neuroblastoma Trial

Journal Article · Tue Jan 01 04:00:00 EST 1991 · Medical and Pediatric Oncology; (United States)

DOI:https://doi.org/10.1002/mpo.2950190203· OSTI ID:5474112

Klingebiel, T; Berthold, F; Treuner, J; Schwabe, D; Fischer, M; Feine, U; Maul, F D; Waters, W; Wehinger, H; Niethammer, D ^[1]

---

1. Eberhard-Karls Univ., Tuebingen (Germany )F.R.

From 1984 to 1989, 47 children with relapsed, refractory, and/or metastasized neuroblastoma were treated with {sup 131}I-metaiodobenzylguanidine (mIBG) in several different treatment combinations. At initial diagnosis, 36 children had Evans stage IV and 11 stage III disease. In 16 of the 47 children, tumor recurred after complete remission prior to mIBG treatment, 26 of 47 progressed from residual or nonresponding tumor, and in 5 of 47 tumor progression during chemotherapy was observed. Altogether the children were treated with a total of 112 courses (range 1-6) with a mean dosage of 8.9 +/- 6.7 mCi/kg body weight/treatment course. Total dose was 283.2 +/- 203.7 mCi for stage III and 388.9 +/- 218.6 mCi for stage IV. Nine of 47 children reached a complete or a very good partial remission (CR and VGPR) from mIBG treatment alone, 13 of 47 achieved partial remission (PR). In an early analysis, 10 patients treated with mIBG in the neuroblastoma trial NB 85 of the German Society of Pediatric Oncology showed no significant difference in survival time compared with 30 conventionally treated children. However, the recent therapy series has been done with higher doses of mIBG, and during improved therapeutic scanning many more bone lesions could be detected than during earlier diagnostic scanning. We conclude that mIBG treatment has not yet fulfilled the expectations for it but still seems for certain indications to be a promising tool to treat neuroblastoma in the future. Moreover, the frontier of neuroblastoma detection is still advancing.

• OSTI ID: 5474112
• Journal Information: Medical and Pediatric Oncology; (United States), Journal Name: Medical and Pediatric Oncology; (United States) Vol. 19:2; ISSN 0098-1532; ISSN MPOND
• Country of Publication: United States
• Language: English

Related Subjects

550600 -- Medicine
550604* -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
AGE GROUPS
ANTINEOPLASTIC DRUGS
AUTONOMIC NERVOUS SYSTEM
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
CHILDREN
COMBINED THERAPY
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
DRUGS
GERMANY
INTERMEDIATE MASS NUCLEI
IODINE 131
IODINE ISOTOPES
ISOTOPES
NEOPLASMS
NERVOUS SYSTEM
NUCLEI
ODD-EVEN NUCLEI
PATIENTS
RADIATION DOSES
RADIOISOTOPES
SURVIVAL CURVES
THERAPY